Valeant goes on defensive against investor critics
It is publicly revealing for the first time the benefits that it gets from some price increases; says it has not been as dependent on drug price increases as analysts' reports claim
San Francisco
AMID an intensifying debate over drug price increases that has brought its business practices to the forefront, Valeant Pharmaceuticals International Inc fired back at critics in the investment community, publicly revealing the benefits that it gets from some price hikes for the first time.
Democrats in the US House of Representatives are pushing to subpoena the company for documents relating to drug price i…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Harvard applications drop 5% after tumultuous year on campus
Australia wants businesses to diversify after China scraps wine tariffs
Japan drugmaker reports two more deaths in supplement scare
Chanel flap bag now costs more than 10,000 euros in Paris
Florida governor, Disney reach settlement in lawsuit over special district
Kobayashi Pharma ordered to recall red yeast rice pills after 2 deaths